Targeted Oncology Therapies
Cancer
Phase 1/2Active
Key Facts
About BioNTech
BioNTech SE is a publicly-traded immunotherapy powerhouse founded by scientists and physicians to translate science into survival through innovative mRNA technologies. The company gained global recognition for its COVID-19 vaccine developed with Pfizer and is now applying its mRNA expertise to cancer immunotherapies and other infectious diseases. With over 25 Phase 2 and Phase 3 oncology trials and a €2.10 billion R&D investment planned for 2025, BioNTech is positioning itself as a leader in personalized cancer treatment and next-generation vaccines.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Shared Antigen mRNA Cancer Vaccines | BioNTech | Phase 2 |
| ARGX-119 | Argenx | Phase 1 |
| Oncology Program | Shionogi | Clinical |
| Bmab (Bevacizumab) | Biocon | Approved |
| Ciforadenant (CPI-444) | Corvus Pharmaceuticals | Phase 1/2 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1 |
| tovecimig | Compass Therapeutics | Clinical |
| CTX-8371 | Compass Therapeutics | Clinical |
| XmAb 14045 | Xencor | Clinical |
| XmAb 13676 | Xencor | Clinical |
| Vibostolimab | Xencor | Clinical |
| PB272 (neratinib, intravenous) | Puma Biotechnology | Not Disclosed |